The effects of haemofiltration on cefazolin levels during cardiopulmonary bypass

Perfusion

Volumn 13, Issue 3, 1998, Pages 176-180

  O'Rullian, James J ^a,b   Wise, Robert K ^a   McCoach, Robert M ^a   Kingsley, Charles P ^a   Williams, Dennis R ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b 9005 Plum Blossom Court ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEPHALOSPORIN DERIVATIVE;

ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; HEMOCONCENTRATION; HEMOFILTRATION; HUMAN; INFECTION RISK; PRIORITY JOURNAL; STERNUM; ULTRAFILTRATION; WOUND INFECTION;

EID: 0031808639     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919801300304     Document Type: Article

References (6)

1. Clar A, Larson DF. Hemofiltration: determinants of drug loss and concentration. J Extra-Corp Technol 1995; 27: 258-63.
2. Golper TA, Bennett WM. Drug removed by arteriovenous haemofiltration. Medical Toxicol 1988; 3: 341-9.
3. Polk RE, Archer GL, Lower R. Cefamandole kinetics during cardiopulmonary bypass. Clin Pharmacol Ther 1978; 23: 473-80.
4. Quintiliani R, Nightingale CH. Cefazolin - diagnosis and treatment. Ann Intern Med 1978; 89: 650-6.
5. Miller KW, McCoy HG, Fischer RP, Lindsay WG. Effect of cardiopulmonary bypass on cefazolin disposition. Clin Pharmacol Ther 1975; 27: 550-6.
6. Golper TA, Continuous arteriovenous hemofiltration in acute renal failure. Am J Kidney Dis 1985; 6: 373-86.